<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114831">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01608295</url>
  </required_header>
  <id_info>
    <org_study_id>VII-IT-02</org_study_id>
    <nct_id>NCT01608295</nct_id>
  </id_info>
  <brief_title>Vilazodone for Treatment of Geriatric Depression</brief_title>
  <official_title>A Pilot Study of Double-blind Comparison of Vilazodone to Paroxetine in Geriatric Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the effects of vilazodone for the treatment of
      depression in older adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 12-week double-blind comparison of a novel antidepressant, vilazodone, to the
      gold-standard drug, paroxetine, for the treatment of geriatric depression. We are interested
      in assessing the difference in response to vilazodone (VLZ) compared to paroxetine (PAR). We
      hope to detect difference in response in primary outcomes (depressed mood) and secondary
      outcomes cognition. We are seeking to examine this directly in 80 older adults (60 years of
      age or older) with major depression with anticipated 60 completers. This proposed trial will
      serve as a pilot study to estimate the efficacy and tolerability of the drug in older
      depressed adults, and use this project for dose-finding in this population.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Depression Rating Scale (HDRS)</measure>
    <time_frame>Each visit for 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>UKU Side-effect Profile</measure>
    <time_frame>Each visit for 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive Measures</measure>
    <time_frame>Baseline and Final Visit</time_frame>
    <description>A battery of neuropsychological tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Biomarkers</measure>
    <time_frame>Baseline and Final Visit</time_frame>
    <description>Blood Tests</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Vilazodone; Viibryd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After screening and baseline test results are reviewed and eligibility criteria are confirmed, medications will be dispensed if patients continue to meet eligibility criteria and sign the informed consent form. All eligible subjects will be randomized to vilazodone or paroxetine group using a computer-generated random assignment scheme, which assigned subjects in a 1:1 ratio to each group. Randomization will be done prior to subject's being assigned to the groups. Doses of the drugs will be adjusted according to individual tolerability and safety.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paroxetine; Paxil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After screening and baseline test results are reviewed and eligibility criteria are confirmed, medications will be dispensed if patients continue to meet eligibility criteria and sign the informed consent form. All eligible subjects will be randomized to vilazodone or paroxetine group using a computer-generated random assignment scheme, which assigned subjects in a 1:1 ratio to each group. Randomization will be done prior to subject's being assigned to the groups. Doses of the drugs will be adjusted according to individual tolerability and safety.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vilazodone; Viibryd</intervention_name>
    <description>Subjects randomized to receive vilazodone blindly will have incremental dose titration of 10mg per day for the 1st week; 20mg per day the 2nd week; 40mg per day for the 3rd-12th week. Doses of the drugs will be adjusted according to individual tolerability and safety.</description>
    <arm_group_label>Vilazodone; Viibryd</arm_group_label>
    <other_name>Vilazodone</other_name>
    <other_name>Viibryd</other_name>
    <other_name>Antidepressant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paroxetine; Paxil</intervention_name>
    <description>Subjects randomized to receive paroxetine blindly will have incremental dose titration of paroxetine 10mg per day for the 1st week; 20mg per day for the 2nd week; and 30mg per day for the 3rd-12 week. Doses of the drugs will be adjusted according to individual tolerability and safety.</description>
    <arm_group_label>Paroxetine; Paxil</arm_group_label>
    <other_name>Paroxetine</other_name>
    <other_name>Paxil</other_name>
    <other_name>Antidepressant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  60 years of age or older

          -  The presence of a major depressive disorder diagnosed according to the DSM-IV
             criteria

          -  A 24-item Hamilton Rating Scale for Depression (HAMD) score of 17 or higher at
             baseline

          -  Mini-Mental State Exam (MMSE) score &gt; 24.

        Exclusion Criteria:

          -  Subjects will be excluded if they had any current and/or lifetime history of other
             psychiatric disorders (except unipolar depression with or without comorbid
             generalized anxiety disorder), or recent unstable medical or neurological disorders;
             any disabilities preventing their participation in the study; diagnosis of MCI/
             dementia; those with known allergic reactions to paroxetine or vilazodone.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helen Lavretsky, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA Semel Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.semel.ucla.edu/latelife</url>
    <description>Double-blind comparison of vilazodone to paroxetine in geriatric depression</description>
  </link>
  <verification_date>November 2015</verification_date>
  <lastchanged_date>November 30, 2015</lastchanged_date>
  <firstreceived_date>May 25, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Helen Lavretsky, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>depressed</keyword>
  <keyword>geriatric</keyword>
  <keyword>older adults</keyword>
  <keyword>antidepressants</keyword>
  <keyword>depression</keyword>
  <keyword>anxious</keyword>
  <keyword>major depressive disorder</keyword>
  <keyword>MDD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paroxetine</mesh_term>
    <mesh_term>Vilazodone Hydrochloride</mesh_term>
    <mesh_term>Antidepressive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
